A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.

A Phase II Study of ABT-751 in Patients With Breast Cancer Refractory to Taxane Regimens

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with breast cancer after having had taxol or taxotere. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Inclusion Criteria

• Stage IIIB or IV breast cancer.
• Recurrent tumor after or while on taxane therapy (taxol or taxotere).
• Able to tolerate normal activities of daily living.
• Adequate bone marrow, kidney and liver function.

Exclusion Criteria

• Pregnant or breast feeding.
• No anti-tumor therapy (including hormonal therapy or Herceptin) within 4 weeks of the start of ABT-751 administration.